Select your country
Select a country to go to the website of the respective STADA sales company.
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (4)
STADA further grows European Consumer Healthcare portfolio by acquiring 16 well-established brands from Sanofi
- Press Release
- STADA is acquiring from Sanofi well-established consumer healthcare brands across 13 countries , including France, Germany, Italy, Poland and Spain
- The portfolio includes cold & flu, skincare and food supplement brands such as Silomat, Mitosyl and Frubiase
- STADA CEO Peter Goldschmidt: “This acquisition further strengthens STADA as a top-five player in Europe’s consumer healthcare market, supports our growth acceleration, and is another proof point of STADA as a go-to-partner.”
Bad Vilbel, 28 June 2021 – STADA is significantly expanding its European Consumer Healthcare portfolio by agreeing to acquire a portfolio of well-established local and regional consumer healthcare brands from Sanofi in countries predominantly in Europe, including France, Germany, Italy, Poland and Spain. The transaction covers 16 brands including Mitosyl ointment and wipes for daily care of sensitive areas and protection against diaper irritation; Silomat dry-cough remedies; Frubiase nutritional supplements for athletes; Modafen cold and flu relief tablets; and the Viscontour allergen-free skincare range.
“This acquisition further strengthens STADA as a top-five player in Europe’s consumer healthcare market, supports our growth acceleration, and is another proof point of STADA as a go-to-partner,” commented STADA’s CEO, Peter Goldschmidt.
“As a broad-based European player with a strong presence in multiple markets, STADA is increasingly a go-to-partner in generics, specialty pharma and consumer healthcare,” Goldschmidt highlighted. “The brands being acquired, and their geographic presence, are well aligned and synergistic with the organic activities in STADA’s core countries.”
No financial details were disclosed of the asset-purchase agreement that includes registrations, trademarks and related commercial rights to the 16 brands. No manufacturing assets or employees are included in the transaction, which is scheduled to close in the third quarter of 2021, subject to approval of relevant regulatory authorities and other customary closing conditions.
STADA’s global Consumer Healthcare head Volker Sydow outlined: “Under STADA’s ownership, we believe there is an excellent opportunity to further strengthen and grow these well-known brands. Through targeted investment, including via digital channels, and product innovation, we believe we can give these brands a new lease of life in their respective niches.”
“STADA’s extensive sales, marketing and distribution network throughout Europe, along with its long-established partnerships with pharmacists, will enable the group to capitalize on the 16 brands’ strong local heritage and brand recognition,” stated STADA’s Head of European Markets, Steffen Wagner.
STADA will also explore synergy potential from transferring manufacturing of certain brands into the group’s existing supply-chain network.
Most of the acquired portfolio’s annual turnover is currently achieved in five European countries: Germany, France, Spain, Italy and Poland.
Cough and cold brands account for more than half of the acquired portfolio’s sales, and derma brands around one third. Other acquired brands include: Lisomucil cough syrup in Italy; Bronchoforton ointment in Germany; Bronchokod syrup in France; and Brolene eye drops and ointment in the UK and Ireland. Also included are Antigongestiva Cusi and Rinocusi in Spain; Acodin in Poland; Nasobol in Switzerland; and Sedotussin in Germany.
“Simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers. We are pleased these brands will continue to be available for consumers as we focus on becoming a fully integrated standalone business,” said Julie Van Ongevalle, Executive Vice-President, Sanofi and Head of Sanofi Consumer Healthcare.
The transaction for these 16 brands from Sanofi comes after STADA last year acquired from GSK 15 well-established consumer healthcare brands across more than 40 countries and multiple therapeutic areas. STADA also recently strengthened its portfolio of vitamin, mineral and supplement (VMS) products by acquiring Czech healthcare company Walmark, which has an international footprint.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 713.3 million. As of 31 December 2020, STADA employed 12,301 people worldwide.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Additional STADA information for journalists:
STADA Arzneimittel AG - Media Relations
61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
Fax: +49 (0) 6101 603-215
Additional STADA information for capital market participants:
STADA Arzneimittel AG - Investor & Creditor Relations
61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
Sanofi Media Relations Contacts:
Phone: +33 (0)6 25 09 14 25
Phone: +1 (908) 981-8745
Sanofi Investor Relations – Paris:
Sanofi Investor Relations – North America:
IR Main Line:
Phone: +33 (0)1 53 77 45 45